{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:24:12Z","timestamp":1779924252642,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To examine the dosimetric feasibility of hypofractionated\/dose escalated radiation therapy in patients with localized prostate carcinoma using simultaneous integrated boost intensity-modulated proton beam therapy (SIB-IMPT) in absence or presence of prostate-rectum spacer.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>IMPT technique was implemented in 23 patients with intermediate- and high-risk prostate cancer treated at West German Proton Therapy Centre from March 2016 till June 2018, using SIB technique prescribing 60 GyRBE and 72\u202fGyRBE in 30 fractions to PTV1 (prostate and seminal vesicle) and PTV2 boost (prostate and proximal seminal vesicle), respectively. In 15 patients, a transperineal injection of hydrogel was applied prior to radiotherapy to increase the distance between prostate and rectum. Planning and all treatments were performed with a 120\u00a0ml fluid-filled endorectal balloon customised daily for each patient. For each patient, 2 lateral IMPT beams were implemented taking a field-specific range uncertainty (RU) into account. Dose volume histograms (DVH) were analyzed for PTV2, PTV2 with range uncertainty margin (PTV2RU), rectum, bladder, right\/left femoral heads, and penile bulb. For late rectal toxicities, the normal tissue complication probabilities (NTCP) were calculated using different biological models. A DVH- and NTCP-based dosimetric comparison was carried out between non-spacer and spacer groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the 23 patients, high-quality plans could be achieved for target volume and for other organs at risk (OARs). For PTV2, the <jats:italic>V<\/jats:italic><jats:sub>107%<\/jats:sub> was 0% and the D<jats:sub>max<\/jats:sub> did not exceed 106.2% of the prescribed dose. The volume PTV2RU covered by 95% of the dose ranged from 96.16 to 99.95%. The conformality index for PTV2RU was 1.12\u2009\u00b1\u20090.057 and the homogeneity index (HI) was 1.04\u2009\u00b1\u20090.014. Rectum D<jats:sub>max<\/jats:sub> and rectal volume receiving 73\u201350\u00a0Gy could be further reduced for the spacer-group. Significant reductions in mean and median rectal NTCPs (stenosis\/necrosis, late rectal bleeding\u2009\u2265\u20092, and late rectal toxicities\u2009\u2265\u20093) were predicted for the spacer group in comparison to the non-spacer group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hypofractionated\/dose escalated radiotherapy with SIB-IMPT is dosimetrically feasible. Further reduction of the rectal volumes receiving high and medium dose levels (73\u201350\u00a0Gy) and rectal NTCP could be achieved through injection of spacers between rectum and prostate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02025-2","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:13:27Z","timestamp":1648808007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dosimetric feasibility of moderately hypofractionated\/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer"],"prefix":"10.1186","volume":"17","author":[{"given":"Dalia","family":"Ahmad Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Jazmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Geismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Heinz","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Steinmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schulze Schleitthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandija","family":"Plaude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Tschirdewahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"1","key":"2025_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2025_CR2","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"ST Peeters","year":"2006","unstructured":"Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","volume":"60","author":"MJ Zelefsky","year":"2011","unstructured":"Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011;60(6):1133\u20139.","journal-title":"Eur Urol"},{"issue":"8","key":"2025_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","volume":"17","author":"S Aluwini","year":"2016","unstructured":"Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464\u201374.","journal-title":"Lancet Oncol"},{"key":"2025_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ijrobp.2018.11.020","volume":"103","author":"RC Wortel","year":"2018","unstructured":"Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2018;103:823\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2025_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.adro.2018.02.004","volume":"3","author":"CE Vargas","year":"2018","unstructured":"Vargas CE, Schmidt MQ, Niska JR, Hartsell WF, Keole SR, Doh L, et al. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer. Adv Radiat Oncol. 2018;3(3):322\u201330.","journal-title":"Adv Radiat Oncol"},{"issue":"29","key":"2025_CR8","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","volume":"36","author":"KE Hoffman","year":"2018","unstructured":"Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36(29):2943\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.rpor.2018.06.008","volume":"23","author":"A Karklelyte","year":"2018","unstructured":"Karklelyte A, Valuckas KP, Griskevicius R, Janulionis E, Aleknavicius E. Acute toxicity and quality of life in high risk prostate cancer patients: updated results of randomized hypofractionation trial. Rep Pract Oncol Radiother. 2018;23(4):284\u20139.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"17","key":"2025_CR10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390.","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","volume":"78","author":"G Arcangeli","year":"2010","unstructured":"Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2025_CR13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol. 2018;8(6):354\u201360.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"2025_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ijrobp.2003.10.011","volume":"59","author":"JD Slater","year":"2004","unstructured":"Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59(2):348\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2025_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","volume":"28","author":"AL Zietman","year":"2010","unstructured":"Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106\u201311.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025_CR16","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1118\/1.4711909","volume":"39","author":"W Liu","year":"2012","unstructured":"Liu W, Li Y, Li X, Cao W, Zhang X. Influence of robust optimization in intensity-modulated proton therapy with different dose delivery techniques. Med Phys. 2012;39(6):3089\u2013101.","journal-title":"Med Phys"},{"issue":"2","key":"2025_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/acm2.12249","volume":"19","author":"MH Li","year":"2018","unstructured":"Li MH, Huang SF, Chang CC, Lin JC, Tsai JT. Variations in dosimetric distribution and plan complexity with collimator angles in hypofractionated volumetric arc radiotherapy for treating prostate cancer. J Appl Clin Med Phys. 2018;19(2):93\u2013102.","journal-title":"J Appl Clin Med Phys"},{"issue":"4","key":"2025_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ijrobp.2004.11.034","volume":"61","author":"XA Li","year":"2005","unstructured":"Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61(4):1251\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1034","key":"2025_CR19","doi-asserted-by":"publisher","first-page":"20130617","DOI":"10.1259\/bjr.20130617","volume":"87","author":"C Onal","year":"2014","unstructured":"Onal C, Sonmez S, Erbay G, Guler OC, Arslan G. Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol. 2014;87(1034):20130617.","journal-title":"Br J Radiol"},{"issue":"5","key":"2025_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00066-012-0081-8","volume":"188","author":"M Geier","year":"2012","unstructured":"Geier M, Astner ST, Duma MN, Jacob V, Nieder C, Putzhammer J, et al. Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol. 2012;188(5):410\u20136.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"2025_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/cam4.278","volume":"3","author":"B Saracino","year":"2014","unstructured":"Saracino B, Petrongari MG, Marzi S, Bruzzaniti V, Sara G, Arcangeli S, et al. Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control. Cancer Med. 2014;3(5):1313\u201321.","journal-title":"Cancer Med"},{"issue":"3","key":"2025_CR22","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.prro.2017.09.007","volume":"8","author":"MG Chang","year":"2018","unstructured":"Chang MG, Mukhopadhyay N, Holdford D, Skinner V, Saraiya S, Moghanaki D, et al. Phase 1\/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost. Pract Radiat Oncol. 2018;8(3):e149\u201357.","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"2025_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00432-017-2375-9","volume":"143","author":"C Franzese","year":"2017","unstructured":"Franzese C, Fogliata A, D\u2019Agostino GR, Di Brina L, Comito T, Navarria P, et al. Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. J Cancer Res Clin Oncol. 2017;143(7):1301\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejmp.2017.09.136","volume":"43","author":"C Baumer","year":"2017","unstructured":"Baumer C, Geismar D, Koska B, Kramer PH, Lambert J, Lemke M, et al. Comprehensive clinical commissioning and validation of the RayStation treatment planning system for proton therapy with active scanning and passive treatment techniques. Phys Med. 2017;43:15\u201324.","journal-title":"Phys Med"},{"issue":"6","key":"2025_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/02841869509127196","volume":"34","author":"AK Agren Cronqvist","year":"1995","unstructured":"Agren Cronqvist AK, Kallman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol. 1995;34(6):851\u201360.","journal-title":"Acta Oncol"},{"issue":"1","key":"2025_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.radonc.2004.08.013","volume":"73","author":"T Rancati","year":"2004","unstructured":"Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73(1):21\u201332.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2025_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0360-3016(00)00510-1","volume":"47","author":"E Dale","year":"2000","unstructured":"Dale E, Hellebust TP, Skjonsberg A, Hogberg T, Olsen DR. Modeling normal tissue complication probability from repetitive computed tomography scans during fractionated high-dose-rate brachytherapy and external beam radiotherapy of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;47(4):963\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2025_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jjco\/hyx181","volume":"48","author":"M Someya","year":"2018","unstructured":"Someya M, Hori M, Gocho T, Nakata K, Tsuchiya T, Kitagawa M, et al. Prediction of acute gastrointestinal and genitourinary radiation toxicity in prostate cancer patients using lymphocyte microRNA. Jpn J Clin Oncol. 2018;48(2):167\u201374.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"2025_CR29","doi-asserted-by":"publisher","first-page":"S319","DOI":"10.1016\/j.ijrobp.2007.07.1382","volume":"69","author":"V Beckendorf","year":"2007","unstructured":"Beckendorf V, Guerif S, Le Prise E, Cossett JM, Le Floch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bey P. Late toxicity in the GETUG 06 randomized trial comparing 70 Gy and 80 Gy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):S319.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2025_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2009.02.025","volume":"76","author":"SL Gulliford","year":"2010","unstructured":"Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2010;76(3):747\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2025_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12094-012-0987-8","volume":"15","author":"V Macias","year":"2013","unstructured":"Macias V, Gonzalez Celador R, Marti-Macia C, Cigarral C, Perez-Romasanta LA. Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy. Clin Transl Oncol. 2013;15(8):643\u201351.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2025_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/030089160909500206","volume":"95","author":"A Ballare","year":"2009","unstructured":"Ballare A, Di Salvo M, Loi G, Ferrari G, Beldi D, Krengli M. Conformal radiotherapy of clinically localized prostate cancer: analysis of rectal and urinary toxicity and correlation with dose-volume parameters. Tumori. 2009;95(2):160\u20138.","journal-title":"Tumori"},{"issue":"3","key":"2025_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0360-3016(00)00700-8","volume":"48","author":"MR Storey","year":"2000","unstructured":"Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2025_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jrr\/rru080","volume":"56","author":"M Someya","year":"2015","unstructured":"Someya M, Hori M, Tateoka K, Nakata K, Takagi M, Saito M, et al. Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res. 2015;56(1):122\u20137.","journal-title":"J Radiat Res"},{"issue":"1","key":"2025_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijrobp.2009.01.048","volume":"76","author":"N Pervez","year":"2010","unstructured":"Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, et al. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(1):57\u201364.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2025_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.radonc.2014.02.011","volume":"111","author":"TJ Strom","year":"2014","unstructured":"Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, et al. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy+\/\u2212intensity modulated radiation therapy. Radiother Oncol. 2014;111(1):126\u201331.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2025_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2025_CR38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2016.02.025","volume":"95","author":"G Habl","year":"2016","unstructured":"Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, et al. Acute toxicity and quality of life in patients with prostate cancer treated with protons or carbon ions in a prospective randomized phase II study\u2014the IPI trial. Int J Radiat Oncol Biol Phys. 2016;95(1):435\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctro.2018.10.006","volume":"14","author":"BGL Vanneste","year":"2019","unstructured":"Vanneste BGL, Buettner F, Pinkawa M, Lambin P, Hoffmann AL. Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. Clin Transl Radiat Oncol. 2019;14:17\u201324.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"2025_CR40","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1120\/jacmp.v13i3.3639","volume":"13","author":"S Qamhiyeh","year":"2012","unstructured":"Qamhiyeh S, Geismar D, Pottgen C, Stuschke M, Farr J. The effects of motion on the dose distribution of proton radiotherapy for prostate cancer. J Appl Clin Med Phys. 2012;13(3):3639.","journal-title":"J Appl Clin Med Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:51:28Z","timestamp":1648821088000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02025-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the local ethical commission. All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors gave consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}